| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2017-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77000fa66a64b192ffbe084abff7fbef |
| publicationDate |
2019-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3502691-A1 |
| titleOfInvention |
Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| abstract |
The present invention relates to a method for assessing whether a critically ill subject is in need of a renal replacement therapy, wherein the method comprises determining in a sample obtained from said subject the level of proadrenomedullin (proADM) or a fragment thereof, preferably the fragment is MR-proADM, wherein said level of proADM or the fragment thereof is indicative of a need of said subject to receive a renal replacement therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116046923-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116046923-B |
| priorityDate |
2017-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |